Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Ítems similars

• Molecular Evolution of Hypoallergenic Hybrid Proteins for Vaccination against Grass Pollen Allergy
  per: Linhart, Birgit, et al.
  Publicat: (2015)
• Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy
  per: Focke-Tejkl, Margarete, et al.
  Publicat: (2015)
• Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG(4) response
  per: Eckl-Dorna, Julia, et al.
  Publicat: (2019)
• Skin test evaluation of a novel peptide carrier–based vaccine, BM32, in grass pollen–allergic patients
  per: Niederberger, Verena, et al.
  Publicat: (2015)
• Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
  per: Niederberger, Verena, et al.
  Publicat: (2018)